Davis Thomas Andrew's Form 4 filing
Genocea Biosciences, Inc. (GNCA) · filed Apr 5, 2022
- Accession no.
- 0001457612-22-000044
- Filed
- Apr 5, 2022
- Trade date
- Apr 4, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $1.36K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis Thomas AndrewCIK 0001338185 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2022 | Common Stock | SSaleDisposed | −1,091 | $1.25 | −$1,363.75 | 68,330 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.